Aida Aydemir

1.1k citations

26 papers · 756 indexed · 1 hit paper · h-index 12

Co-authors: F. Eckstein Ali Guermazi Marc C. Hochberg Stephen Wax Hans Guehring I. Byrjalsen Asger Reinstrup Bihlet Patricia Fleuranceau-Morel
Topics: Osteoarthritis Treatment and Mechanisms (7 papers)Knee injuries and reconstruction techniques (5 papers)Multiple Sclerosis Research Studies (5 papers)
Cited by: Rheumatology Nephrology Pharmacology
Journals: JAMASHILAP Revista de lepidopterologíaNeurology
Partner nations: United States Germany United Kingdom

In The Last Decade

Aida Aydemir

25 papers receiving 751 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis

2019 242 citations Marc C. Hochberg, Ali Guermazi et al. JAMA profile →

Peers

Countries citing papers authored by Aida Aydemir

Since Specialization

Citations

This map shows the geographic impact of Aida Aydemir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aida Aydemir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aida Aydemir more than expected).

Fields of papers citing papers by Aida Aydemir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aida Aydemir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aida Aydemir. The network helps show where Aida Aydemir may publish in the future.

Co-authorship network of co-authors of Aida Aydemir

This figure shows the co-authorship network connecting the top 25 collaborators of Aida Aydemir. A scholar is included among the top collaborators of Aida Aydemir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aida Aydemir. Aida Aydemir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study 2023 ·Multiple Sclerosis Journal ·Gavin Giovannoni,Alexey Boyко,Jorge Correale,Gilles Edan,Mark S. Freedman,Xavier Montalbán,Kottil Rammohan,Dusan Stefoski,Bassem Yamout,Thomas Leist,Aida Aydemir,(unknown),Elisabetta Verdun di Cantogno	23
2	A Plain Language Summary on Assessing the Long-Term Effectiveness of Cladribine Tablets in People Living with Relapsing Multiple Sclerosis: The CLASSIC-MS Study 2023 ·Neurodegenerative Disease Management ·Gavin Giovannoni,Alexey Boyко,Jorge Correale,Gilles Edan,Mark S. Freedman,Xavier Montalbán,Kottil Rammohan,Dusan Stefoski,Bassem Yamout,Thomas Leist,Aida Aydemir,(unknown),Elisabetta Verdun di Cantogno	1
3	Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo (Standard‐of‐Care) data to enable model‐informed drug development 2022 ·CPT Pharmacometrics & Systems Pharmacology ·Kosalaram Goteti,Jonathan French,(unknown),Ying Li,Florence Casset‐Semanaz,Aida Aydemir,Robert Townsend,(unknown),Matthew Studham,(unknown),Amy Kao,Marc R. Gastonguay,Pascal Girard,Lisa J. Benincosa,Karthik Venkatakrishnan	7
4	Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria 2022 ·Kidney International Reports ·Jonathan Barratt,James A. Tumlin,Yusuke Suzuki,Amy Kao,Aida Aydemir,(unknown),Hulin Jin,Hans Gühring,Gerald B. Appel	67
5	The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets 2022 ·Current Medical Research and Opinion ·Helmut Butzkueven,Nicholas Moore,Aida Aydemir,(unknown),Irene D. Bezemer,Pasi K. Korhonen,Meritxell Sabidó,(unknown)	4
6	CLASSIC-MS: Long-term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis who Received Cladribine Tablets in Phase III Parent Trials (1919) 2021 ·Neurology ·Gavin Giovannoni,Aida Aydemir,Elisabetta Verdun di Cantogno,Thomas Leist	3
7	Predicting knee replacement in participants eligible for disease-modifying osteoarthritis drug treatment with structural endpoints 2020 ·Osteoarthritis and Cartilage ·C. Kent Kwoh,Hans Guehring,Aida Aydemir,Michael J. Hannon,F. Eckstein,Marc C. Hochberg	14
8	Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations, based on sqMRI assessment over 2 years 2020 ·Osteoarthritis and Cartilage ·Frank W. Roemer,(unknown),Aida Aydemir,Stephen Wax,Marc C. Hochberg,M.D. Crema,Ali Guermazi	19
9	A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach 2020 ·SHILAP Revista de lepidopterología ·Lynn Rochester,Claudia Mazzà,Arne Mueller,Brian Caulfield,Marie Mc Carthy,Clemens Becker,Ram R. Miller,Paolo Piraino,Marco Viceconti,(unknown),Judith García‐Aymerich,Aida Aydemir,Beatrix Vereijken,(unknown),Nadir Ammour,Michael P. Jackson,(unknown),Ronenn Roubenoff	71
10	Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial 2020 ·Annals of the Rheumatic Diseases ·F. Eckstein,(unknown),Aida Aydemir,W. Wirth,S. Maschek,Marc C. Hochberg	59
11	MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA 2020 ·Nephrology Dialysis Transplantation ·Jonathan Barratt,James A. Tumlin,Yusuke Suzuki,Amy Kao,Aida Aydemir,(unknown),Gerald B. Appel	11
12	24-Week Interim Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Atacicept in Patients with IgA Nephropathy and Persistent Proteinuria 2020 ·Journal of the American Society of Nephrology ·Jonathan Barratt,James A. Tumlin,Yusuke Suzuki,Amy Kao,Aida Aydemir,(unknown),Gerald B. Appel	2
13	Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritisbreakdown → 2019 ·JAMA ·Marc C. Hochberg,Ali Guermazi,Hans Guehring,Aida Aydemir,Stephen Wax,Patricia Fleuranceau-Morel,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,F. Eckstein	242
14	Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of femorotibial location: a post-hoc analysis of a randomized, placebo-controlled phase ii clinical trial 2018 ·Osteoarthritis and Cartilage ·F. Eckstein,Stephen Wax,Aida Aydemir,W. Wirth,S. Maschek,Marc C. Hochberg	3
15	Efficacy and safety of intra-articular Sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomized, placebo-controlled, phase II study 2018 ·Osteoarthritis and Cartilage ·Marc C. Hochberg,Ali Guermazi,Hans Guehring,Aida Aydemir,Stephen Wax,Patricia Fleuranceau-Morel,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,F. Eckstein	5
16	OP0059 Efficacy and safety of intra-articular sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomised, placebo-controlled, phase ii study 2018 ·Annals of the Rheumatic Diseases ·Marc C. Hochberg,Ali Guermazi,Hans Guehring,Aida Aydemir,Stephen Wax,Patricia Fleuranceau-Morel,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,F. Eckstein	10
17	Structural effects of sprifermin in knee osteoarthritis: a post-hoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial 2016 ·BMC Musculoskeletal Disorders ·Frank W. Roemer,Aida Aydemir,Stefan Lohmander,M.D. Crema,Monica Marra,Norma Muurahainen,David T. Felson,F. Eckstein,Ali Guermazi	42
18	A first-in-human, double-blind, randomised, placebo-controlled, dose ascending study of intra-articular rhFGF18 (sprifermin) in patients with advanced knee osteoarthritis. 2016 ·PubMed ·Leif Dahlberg,Aida Aydemir,Norma Muurahainen,Hans Gühring,(unknown),(unknown),C. Ladel,Jukka S. Jurvelin	55
19	The folate status of reproductive-aged women in a randomised trial of a folate-fortified oral contraceptive: dietary and blood assessments 2013 ·Public Health Nutrition ·Paula M. Castaño,Aida Aydemir,Carole Sampson-Landers,R. Lynen	6
20	Prevalence of Drug-Resistant and Nonsubtype B HIV Strains in Antiretroviral-Naïve, HIV-Infected Individuals in New York State 2007 ·AIDS Patient Care and STDs ·Monica M. Parker,(unknown),Andrew Reilly,Harold W. Horowitz,(unknown),(unknown),(unknown),Joe S. Smith,Daryl M. Lamson,Aida Aydemir,(unknown),Bruce Agins,George L. Drusano,Jill Taylor,(unknown)	16

About Aida Aydemir

Aida Aydemir is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Nephrology, having authored 26 papers that have together received 756 indexed citations. Recurring topics across this work include Osteoarthritis Treatment and Mechanisms (7 papers), Knee injuries and reconstruction techniques (5 papers) and Multiple Sclerosis Research Studies (5 papers). The work is most often cited by research in Rheumatology (466 citations), Nephrology (81 citations) and Pharmacology (146 citations). Aida Aydemir has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include F. Eckstein, Ali Guermazi, Marc C. Hochberg, Stephen Wax, Hans Guehring, I. Byrjalsen, Asger Reinstrup Bihlet, Patricia Fleuranceau-Morel, J.R. Andersen and S. Maschek. Their work appears in journals such as JAMA, SHILAP Revista de lepidopterología and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact